Cargando…
Topographical Mapping of 436 Newly Diagnosed IDH Wildtype Glioblastoma With vs. Without MGMT Promoter Methylation
Introduction: O(6)-methylguanine-methyltransferase (MGMT) promoter methylation and isocitrate dehydrogenase (IDH) mutation status are important prognostic factors for patients with glioblastoma. There are conflicting reports about a differential topographical distribution of glioblastoma with vs. wi...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7235346/ https://www.ncbi.nlm.nih.gov/pubmed/32477929 http://dx.doi.org/10.3389/fonc.2020.00596 |
_version_ | 1783535946950508544 |
---|---|
author | Incekara, Fatih van der Voort, Sebastian R. Dubbink, Hendrikus J. Atmodimedjo, Peggy N. Nandoe Tewarie, Rishi Lycklama, Geert Vincent, Arnaud J. P. E. Kros, Johan M. Klein, Stefan van den Bent, Martin Smits, Marion |
author_facet | Incekara, Fatih van der Voort, Sebastian R. Dubbink, Hendrikus J. Atmodimedjo, Peggy N. Nandoe Tewarie, Rishi Lycklama, Geert Vincent, Arnaud J. P. E. Kros, Johan M. Klein, Stefan van den Bent, Martin Smits, Marion |
author_sort | Incekara, Fatih |
collection | PubMed |
description | Introduction: O(6)-methylguanine-methyltransferase (MGMT) promoter methylation and isocitrate dehydrogenase (IDH) mutation status are important prognostic factors for patients with glioblastoma. There are conflicting reports about a differential topographical distribution of glioblastoma with vs. without MGMT promoter methylation, possibly caused by molecular heterogeneity in glioblastoma populations. We initiated this study to re-evaluate the topographical distribution of glioblastoma with vs. without MGMT promoter methylation in light of the updated WHO 2016 classification. Methods: Preoperative T2-weighted/FLAIR and postcontrast T1-weighted MRI scans of patients aged 18 year or older with IDH wildtype glioblastoma were collected. Tumors were semi-automatically segmented, and the topographical distribution between glioblastoma with vs. without MGMT promoter methylation was visualized using frequency heatmaps. Then, voxel-wise differences were analyzed using permutation testing with Threshold Free Cluster Enhancement. Results: Four hundred thirty-six IDH wildtype glioblastoma patients were included; 211 with and 225 without MGMT promoter methylation. Visual examination suggested that when compared with MGMT unmethylated glioblastoma, MGMT methylated glioblastoma were more frequently located near bifrontal and left occipital periventricular area and less frequently near the right occipital periventricular area. Statistical analyses, however, showed no significant difference in topographical distribution between MGMT methylated vs. MGMT unmethylated glioblastoma. Conclusions: This study re-evaluated the topographical distribution of MGMT promoter methylation in 436 newly diagnosed IDH wildtype glioblastoma, which is the largest homogenous IDH wildtype glioblastoma population to date. There was no statistically significant difference in anatomical localization between MGMT methylated vs. unmethylated IDH wildtype glioblastoma. |
format | Online Article Text |
id | pubmed-7235346 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-72353462020-05-29 Topographical Mapping of 436 Newly Diagnosed IDH Wildtype Glioblastoma With vs. Without MGMT Promoter Methylation Incekara, Fatih van der Voort, Sebastian R. Dubbink, Hendrikus J. Atmodimedjo, Peggy N. Nandoe Tewarie, Rishi Lycklama, Geert Vincent, Arnaud J. P. E. Kros, Johan M. Klein, Stefan van den Bent, Martin Smits, Marion Front Oncol Oncology Introduction: O(6)-methylguanine-methyltransferase (MGMT) promoter methylation and isocitrate dehydrogenase (IDH) mutation status are important prognostic factors for patients with glioblastoma. There are conflicting reports about a differential topographical distribution of glioblastoma with vs. without MGMT promoter methylation, possibly caused by molecular heterogeneity in glioblastoma populations. We initiated this study to re-evaluate the topographical distribution of glioblastoma with vs. without MGMT promoter methylation in light of the updated WHO 2016 classification. Methods: Preoperative T2-weighted/FLAIR and postcontrast T1-weighted MRI scans of patients aged 18 year or older with IDH wildtype glioblastoma were collected. Tumors were semi-automatically segmented, and the topographical distribution between glioblastoma with vs. without MGMT promoter methylation was visualized using frequency heatmaps. Then, voxel-wise differences were analyzed using permutation testing with Threshold Free Cluster Enhancement. Results: Four hundred thirty-six IDH wildtype glioblastoma patients were included; 211 with and 225 without MGMT promoter methylation. Visual examination suggested that when compared with MGMT unmethylated glioblastoma, MGMT methylated glioblastoma were more frequently located near bifrontal and left occipital periventricular area and less frequently near the right occipital periventricular area. Statistical analyses, however, showed no significant difference in topographical distribution between MGMT methylated vs. MGMT unmethylated glioblastoma. Conclusions: This study re-evaluated the topographical distribution of MGMT promoter methylation in 436 newly diagnosed IDH wildtype glioblastoma, which is the largest homogenous IDH wildtype glioblastoma population to date. There was no statistically significant difference in anatomical localization between MGMT methylated vs. unmethylated IDH wildtype glioblastoma. Frontiers Media S.A. 2020-05-12 /pmc/articles/PMC7235346/ /pubmed/32477929 http://dx.doi.org/10.3389/fonc.2020.00596 Text en Copyright © 2020 Incekara, van der Voort, Dubbink, Atmodimedjo, Nandoe Tewarie, Lycklama, Vincent, Kros, Klein, van den Bent and Smits. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Incekara, Fatih van der Voort, Sebastian R. Dubbink, Hendrikus J. Atmodimedjo, Peggy N. Nandoe Tewarie, Rishi Lycklama, Geert Vincent, Arnaud J. P. E. Kros, Johan M. Klein, Stefan van den Bent, Martin Smits, Marion Topographical Mapping of 436 Newly Diagnosed IDH Wildtype Glioblastoma With vs. Without MGMT Promoter Methylation |
title | Topographical Mapping of 436 Newly Diagnosed IDH Wildtype Glioblastoma With vs. Without MGMT Promoter Methylation |
title_full | Topographical Mapping of 436 Newly Diagnosed IDH Wildtype Glioblastoma With vs. Without MGMT Promoter Methylation |
title_fullStr | Topographical Mapping of 436 Newly Diagnosed IDH Wildtype Glioblastoma With vs. Without MGMT Promoter Methylation |
title_full_unstemmed | Topographical Mapping of 436 Newly Diagnosed IDH Wildtype Glioblastoma With vs. Without MGMT Promoter Methylation |
title_short | Topographical Mapping of 436 Newly Diagnosed IDH Wildtype Glioblastoma With vs. Without MGMT Promoter Methylation |
title_sort | topographical mapping of 436 newly diagnosed idh wildtype glioblastoma with vs. without mgmt promoter methylation |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7235346/ https://www.ncbi.nlm.nih.gov/pubmed/32477929 http://dx.doi.org/10.3389/fonc.2020.00596 |
work_keys_str_mv | AT incekarafatih topographicalmappingof436newlydiagnosedidhwildtypeglioblastomawithvswithoutmgmtpromotermethylation AT vandervoortsebastianr topographicalmappingof436newlydiagnosedidhwildtypeglioblastomawithvswithoutmgmtpromotermethylation AT dubbinkhendrikusj topographicalmappingof436newlydiagnosedidhwildtypeglioblastomawithvswithoutmgmtpromotermethylation AT atmodimedjopeggyn topographicalmappingof436newlydiagnosedidhwildtypeglioblastomawithvswithoutmgmtpromotermethylation AT nandoetewarierishi topographicalmappingof436newlydiagnosedidhwildtypeglioblastomawithvswithoutmgmtpromotermethylation AT lycklamageert topographicalmappingof436newlydiagnosedidhwildtypeglioblastomawithvswithoutmgmtpromotermethylation AT vincentarnaudjpe topographicalmappingof436newlydiagnosedidhwildtypeglioblastomawithvswithoutmgmtpromotermethylation AT krosjohanm topographicalmappingof436newlydiagnosedidhwildtypeglioblastomawithvswithoutmgmtpromotermethylation AT kleinstefan topographicalmappingof436newlydiagnosedidhwildtypeglioblastomawithvswithoutmgmtpromotermethylation AT vandenbentmartin topographicalmappingof436newlydiagnosedidhwildtypeglioblastomawithvswithoutmgmtpromotermethylation AT smitsmarion topographicalmappingof436newlydiagnosedidhwildtypeglioblastomawithvswithoutmgmtpromotermethylation |